Latest News on LFST

Financial News Based On Company


Advertisement
Advertisement

Lifestance Health director Burdick sells $1.78M in stock

https://www.investing.com/news/insider-trading-news/lifestance-health-director-burdick-sells-178m-in-stock-93CH-5037768
Kenneth A. Burdick, a director at LifeStance Health Group, Inc., recently sold 124,228 shares of the company's common stock for approximately $1.78 million. This transaction occurred on November 16, 2026, with shares sold at an average price of $14.31. The sale follows a significant surge in LifeStance shares over the past year, and the company recently reported strong Q3 2026 earnings, leading to an increased full-year outlook.

LifeStance Director Sold Shares Worth Over $1.7M

https://www.tradingview.com/news/tradingview:a837af92b9b31:0-lifestance-director-sold-shares-worth-over-1-7m/
Kenneth A. Burdick, a director of LifeStance Health Group, sold 124,228 shares of common stock on November 16, 2026, for a total of $1,777,703. The shares were sold at a weighted average price of $14.31 per share. Following the transaction, Burdick directly owned 3,472,038 shares and indirectly owned 46,511 shares through Burdick Family LLC.

Form 4 Lifestance Health Group Inc: Kenneth A. Burdick (Director) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-kenneth-a-burdick-director-for-16-november-93CH-4968604
This article reports on a Form 4 filing for Lifestance Health Group Inc. regarding transactions made by Kenneth A. Burdick, a director, on November 16. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by its insiders. The article provides this information without further details on the nature of the transactions.

Lifestance Health director Burdick sells $1.78M in stock By Investing.com

https://ca.investing.com/news/stock-market-news/lifestance-health-director-burdick-sells-178m-in-stock-93CH-4968596
Kenneth A. Burdick, a director at LifeStance Health Group, Inc., recently sold 124,228 shares of the company's common stock for approximately $1.78 million. The transaction, which occurred on November 16, 2026, involved shares sold at a weighted average price of $14.31. This sale follows a significant 123% surge in LifeStance shares over the past year, with the stock trading near its 52-week high.

Lifestance Health director Burdick sells $1.78M in stock By Investing.com

https://in.investing.com/news/stock-market-news/lifestance-health-director-burdick-sells-178m-in-stock-93CH-5714194
Kenneth A. Burdick, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), sold 124,228 shares of the company's common stock for approximately $1.78 million on November 16, 2026. This transaction occurred after LifeStance shares had surged 123% over the past year and gained 96% year-to-date. The company recently reported strong third-quarter 2026 earnings, exceeding analyst expectations and leading BMO Capital to raise its price target.
Advertisement

Form 4 Lifestance Health Group Inc: Kenneth A. Burdick (Director) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-kenneth-a-burdick-director-for-16-november-93CH-4992268
This article reports on a Form 4 filing for Lifestance Health Group Inc, indicating that Director Kenneth A. Burdick had a transaction on November 16. The brief announcement provides no further details on the nature of the transaction.

Form 4 Lifestance Health Group Inc: TPG GP A, LLC (10% Owner) For: 12 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-tpg-gp-a-llc-10-owner-for-12-november-93CH-5708843
This article reports on a Form 4 filing for Lifestance Health Group Inc (LFST), detailing that TPG GP A, LLC, a 10% owner, made a transaction on November 12. The filing is an official notification of changes in ownership of company stock by an insider. The specific details of the transaction are not provided within this summary, but the article points to the official filing for further information.

Form 144 LifeStance Health Group For: 17 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-lifestance-health-group-for-17-november-93CH-5709009
This article from Investing.com reports on the filing of Form 144 for LifeStance Health Group (LFST) on November 17, 2026. Form 144 indicates an intent to sell restricted or controlled securities, often by company insiders. The article notes a 2.84% increase for LFST.

Precision Trading with Lifestance Health Group Inc. (LFST) Risk Zones

https://news.stocktradersdaily.com/news_release/43/Precision_Trading_with_Lifestance_Health_Group_Inc._LFST_Risk_Zones_111626113801_1794890281.html
This article provides a detailed analysis of Lifestance Health Group Inc. (LFST) using AI models to generate three distinct trading strategies for different risk profiles. It highlights a weak near-term sentiment with potential shifts in mid and long-term outlook, identifying an exceptional short setup. The report includes specific entry, target, and stop loss levels for position trading, momentum breakout, and risk hedging strategies.

Form 4 Lifestance Health Group Inc: Kenneth A. Burdick (Director) For: 12 November

https://in.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-kenneth-a-burdick-director-for-12-november-93CH-5708247
This article reports a Form 4 filing for Lifestance Health Group Inc., indicating an insider transaction by Kenneth A. Burdick, a director, on November 12. The specific details of the transaction are not provided, as the article serves as a brief alert to the filing.
Advertisement

Director Kenneth Burdick sells $2.28M in LifeStance Health stock By Investing.com

https://ca.investing.com/news/stock-market-news/director-kenneth-burdick-sells-228m-in-lifestance-health-stock-93CH-4962318
Kenneth A. Burdick, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), sold approximately $2.28 million worth of company stock, involving 159,624 shares at a weighted average price of $14.31. This sale occurred shortly after Burdick acquired nearly 3 million shares through stock option exercises valued at $22.83 million. LifeStance Health recently reported strong Q3 2026 earnings, surpassing Wall Street expectations, which led BMO Capital to raise its price target for the stock to $16.00.

Form 4 Lifestance Health Group Inc: Kenneth A. Burdick (Director) For: 12 November

https://uk.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-kenneth-a-burdick-director-for-12-november-93CH-4986229
This article reports on a Form 4 filing for Lifestance Health Group Inc, indicating activity by director Kenneth A. Burdick related to November 12. The brief piece includes the stock symbol LFST, which experienced a -4.47% change.

Director Kenneth A. Burdick plans to sell 124,228 LifeStance (LFST) shares.

https://www.stocktitan.net/sec-filings/LFST/144-life-stance-health-group-inc-sec-filing-8bbfd97472dd.html
Kenneth A. Burdick, a director at LifeStance Health Group, Inc. (LFST), has filed an SEC Form 144 indicating his intention to sell 124,228 common shares on or about November 16, 2026, with an estimated market value of $1,778,017.78. These shares were acquired through a stock option exercise on November 12, 2026. The filing also details three prior sales made by Burdick in November 2026, totaling over $4.3 million.

A passive holder reports 16.6 million LifeStance (LFST) shares.

https://www.stocktitan.net/sec-filings/LFST/schedule-13g-a-life-stance-health-group-inc-amended-passive-investmen-55866a666410.html
Summit Partners, L.P. has reported a beneficial ownership of 16,623,824 shares, or 4.37%, in LifeStance Health Group, Inc. (LFST) through a Schedule 13G/A filing. This percentage is based on 380,190,724 shares outstanding as of October 28, 2026. The filing details shared voting and dispositive power among several Summit Partners funds, with individual committee members disclaiming beneficial ownership.

Form 4 Lifestance Health Group Inc: Ryan Pardo (Officer) For: 10 November

https://uk.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-ryan-pardo-officer-for-10-november-93CH-4982323
This article reports on a Form 4 filing for Lifestance Health Group Inc. concerning an officer, Ryan Pardo, for transactions made on November 10. The filing indicates insider trading activity for the company, Lifestance Health Group Inc. (LFST).
Advertisement

LFST: LifeStance Health Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

https://www.quantisnow.com/insight/lifestance-health-group-inc-filed-sec-form-8-k-other-events-6788472
LifeStance Health Group Inc. (LFST) filed an SEC Form 8-K detailing an underwritten offering where selling stockholders sold 45,000,000 common shares. The company itself bought back 2,000,000 of these shares but received no proceeds from the offering. This transaction primarily moved existing shares between holders rather than adding new ones, which could add selling pressure on the stock.

After stock vesting, LifeStance (LFST) officer Lisa Miller proposes selling 14,663 shares.

https://www.stocktitan.net/sec-filings/LFST/144-life-stance-health-group-inc-sec-filing-a4acfae92a79.html
LifeStance Health Group, Inc. officer Lisa Miller has proposed selling 14,663 common shares, valued at approximately $215,252.84, following the vesting of restricted stock on November 10, 2026. The proposed sale date is November 11, 2026, with Fidelity Brokerage Services LLC listed as the broker. This transaction is governed by a Rule 10b5-1 plan adopted on May 7, 2026.

After exercising options, LifeStance (LFST) director proposes selling 75,000 shares.

https://www.stocktitan.net/sec-filings/LFST/144-life-stance-health-group-inc-sec-filing-143d29f1d38b.html
LifeStance Health Group, Inc. (LFST) director Kenneth A. Burdick has proposed selling 75,000 common shares, valued at approximately $1.10 million, after acquiring them through a stock option exercise on November 10, 2026. This proposed sale follows prior sales by Burdick of 500,000 shares in August 2026 and 66,589 shares in November 2026. The Form 144 filing outlines the details of the transaction and Burdick's prior sales.

An investor proposes selling 2.22M LifeStance (LFST) shares.

https://www.stocktitan.net/sec-filings/LFST/144-life-stance-health-group-inc-sec-filing-ef830147b8f8.html
LifeStance Health Group, Inc. (LFST) investor Kimberly Pardo has proposed selling 2,216,585 common shares, valued at approximately $31.9 million, through the Kimberly Pardo Irrev Trust. The proposed sale has an approximate date of November 10, 2026, and was filed via a Form 144 SEC notice. The filing also notes a Rule 10b5-1 plan adoption date of August 11, 2026.

Form 144 LIFESTANCE HEALTH GROUP For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-lifestance-health-group-for-10-november-93CH-4947191
This article announces the filing of Form 144 for Lifestance Health Group on November 10. The content is brief and serves primarily as an alert for this financial filing, without providing further details or analysis. It also includes general market data and related news headlines from Investing.com.
Advertisement

An officer proposes selling 587,920 LifeStance (LFST) shares from a family trust.

https://www.stocktitan.net/sec-filings/LFST/144-life-stance-health-group-inc-sec-filing-dfb570795e46.html
LifeStance Health Group, Inc. (LFST) officer Ryan Pardo has proposed selling 587,920 common shares from the Pardo Family Rev Trust, valued at approximately $8.47 million. The proposed sale date is November 10, 2026, with the Rule 10b5-1 plan adopted on August 11, 2026. Merrill Lynch Pierce Fenner & Smith is listed as the broker for this transaction.

Form 4 Lifestance Health Group Inc For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-for-10-november-93CH-4946392
This article reports on a Form 4 filing for Lifestance Health Group Inc. on November 10. The filing, available via Investing.com, likely details insider transactions or changes in beneficial ownership for the company (LFST). The content is primarily a placeholder for the actual Form 4 data, emphasizing its availability.

Form 4 Lifestance Health Group Inc For: 10 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-for-10-november-93CH-5693658
This article reports on the filing of Form 4 for Lifestance Health Group Inc. on November 10th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The article also mentions the stock symbol LFST and its current performance.

LifeStance Health prices secondary offering of 45M shares at $13.12

https://www.streetinsider.com/Equity+Offerings/LifeStance+Health+prices+secondary+offering+of+45M+shares+at+%2413.12/27312420.html
LifeStance Health Group (Nasdaq: LFST) announced the pricing of a secondary public offering of 45,000,000 shares of common stock at $13.12 per share. The shares are being sold by existing stockholders, and LifeStance will not receive any proceeds. The company has also agreed to repurchase 2,000,000 shares from the selling stockholders at the same price.

LifeStance Health Group Announces Pricing of Secondary Public Offering

https://www.stocktitan.net/news/LFST/life-stance-health-group-announces-pricing-of-secondary-public-6b6ki9qmavf7.html
LifeStance Health Group (Nasdaq: LFST) has announced the pricing of a secondary public offering of 45,000,000 shares of common stock by certain existing stockholders at $13.12 per share. The company itself is not selling shares and will not receive any proceeds from the offering. LifeStance has, however, agreed to repurchase 2,000,000 shares from the underwriters, with both transactions expected to close around November 12, 2026.
Advertisement

LifeStance Health prices 45M share secondary offering at $13.12

https://www.investing.com/news/company-news/lifestance-health-prices-45m-share-secondary-offering-at-1312-93CH-5012368
LifeStance Health Group, Inc. (NASDAQ:LFST) announced the pricing of a secondary public offering of 45,000,000 shares of common stock at $13.12 per share by certain stockholders. The company itself will not sell any shares or receive proceeds from this offering; all proceeds will go to the selling stockholders. LifeStance has agreed to repurchase 2,000,000 shares from the underwriters, a transaction contingent on the completion of the offering, which is expected to close around November 12, 2026.

Form 4 Lifestance Health Group Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-for-9-november-93CH-4942995
This article from Investing.com announces the filing of a Form 4 for Lifestance Health Group Inc. on November 9. The document, which is an SEC filing, typically discloses changes in ownership of company stock by insiders. The article provides the title and date of the filing.

Form 4 Lifestance Health Group Inc For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-lifestance-health-group-inc-for-9-november-93CH-5690515
This article reports on a Form 4 filing for Lifestance Health Group Inc (LFST) on November 9, 2026. Form 4s disclose changes in beneficial ownership of a company's securities by corporate insiders, including directors, officers, and 10%+ shareholders. The article is brief and primarily serves as an announcement for the filing.

LifeStance Health Group Announces Launch of Secondary Public Offering

https://www.globenewswire.com/news-release/2026/11/09/3398205/0/en/lifestance-health-group-announces-launch-of-secondary-public-offering.html
LifeStance Health Group (Nasdaq: LFST) has announced a secondary public offering where certain stockholders will offer 45,000,000 shares of common stock. The company itself is not selling shares or receiving any proceeds from this offering. Concurrently, LifeStance has authorized the purchase of 2,000,000 shares from the underwriters, subject to the offering's completion.

LifeStance Health Group Announces Pricing of Secondary Public Offering

https://www.globenewswire.com/news-release/2026/11/09/3398466/0/en/lifestance-health-group-announces-pricing-of-secondary-public-offering.html
LifeStance Health Group (Nasdaq: LFST) has announced the pricing of a secondary public offering of 45,000,000 shares of its common stock at $13.12 per share. The proceeds from this offering will go entirely to the Selling Stockholders, as the company is not selling any shares. Additionally, LifeStance has agreed to repurchase 2,000,000 shares from the underwriters, conditioned upon the completion of the offering.
Advertisement

LifeStance Sees 2027 Growth Near Low End as EHR Shift Weighs

https://www.tokenpost.com/news/business/50640
LifeStance Health Group, Inc. anticipates its 2027 growth will be at the lower end of its mid-teens long-term range, with its new electronic health record (EHR) system expected to reduce growth by 1 to 2 percentage points. The company's CFO, Ryan McGroarty, provided this estimate during a recent earnings call, emphasizing that the EHR rollout will be phased throughout 2027 to minimize disruption. LifeStance also raised its 2026 revenue outlook to $1.741 billion to $1.761 billion.

BMO raises Lifestance Health stock price target on strong results By Investing.com

https://ca.investing.com/news/stock-market-news/bmo-raises-lifestance-health-stock-price-target-on-strong-results-93CH-4939553
BMO Capital has increased its price target for Lifestance Health Group (NASDAQ:LFST) to $16.00 from $13.00, maintaining an Outperform rating due to strong third-quarter results. The company's revenue and EBITDA significantly exceeded consensus estimates, leading management to raise its full-year outlook. Despite anticipated headwinds from a new electronic health record system in 2027, BMO expects momentum to largely continue.

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:566b923ff094b:0-what-lifestance-health-group-lfst-said-on-its-q3-earnings-call/
LifeStance Health Group (LFST) reported strong third-quarter results with 25% revenue growth and a 70% increase in adjusted EBITDA, leading to a raised full-year 2026 outlook. The company saw significant growth in patient visits and revenue per visit, while also expanding its clinician base. Looking ahead, LifeStance anticipates that its planned electronic health record transition in 2027 will temper revenue growth, but expects continued margin expansion and growth in specialty services.

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:566b923ff094b:0-what-lifestance-health-group-lfst-said-on-its-q3-earnings-call/
LifeStance Health Group (LFST) reported strong Q3 earnings with a 25% revenue increase and raised its full-year 2026 outlook. The company, however, anticipates a slight tempering of revenue growth in 2027 due to a planned electronic health record system transition. LifeStance also expanded specialty services and its presence into a new state.

LifeStance Health Gr Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62922782/lifestance-health-gr-q3-2026-earnings-call-transcript
LifeStance Health Group reported a strong Q3 2026 with 25% revenue growth to $456 million and adjusted EBITDA margins of 15%, leading them to raise full-year guidance. The company expanded its clinician base to over 8,800 and is leveraging technology and geographic expansion to improve mental health care access. Despite a temporary revenue growth impact from a new EHR implementation in 2027, management expects continued margin expansion and sustained earnings growth.
Advertisement

LifeStance Health Group, Inc. (LFST) Tops Q3 EPS by 2c; Offers Guidance

https://www.streetinsider.com/Earnings/LifeStance+Health+Group%2C+Inc.+%28LFST%29+Tops+Q3+EPS+by+2c%3B+Offers+Guidance/27294126.html
LifeStance Health Group, Inc. (LFST) reported strong Q3 2026 results, exceeding analyst expectations with an EPS of $0.06 and revenue of $455.86 million. The company also provided optimistic guidance for FY2026, projecting revenue between $1.74-1.76 billion, and Q4 2026 revenue of $446-466 million, both above consensus estimates.

LifeStance Health: Q3 Earnings Snapshot

https://sg.finance.yahoo.com/news/lifestance-health-q3-earnings-snapshot-111331828.html
LifeStance Health Group Inc. (LFST) reported strong third-quarter results, with net income of $22.4 million, or 6 cents per share, surpassing analyst expectations of 3 cents per share. The outpatient mental health services provider also exceeded revenue forecasts, posting $455.9 million against an expected $428.8 million. The company provided optimistic revenue guidance for the current quarter and the full year.

LifeStance Health Group (LFST) Tops Q3 Earnings and Revenue Estimates

https://finance.yahoo.com/healthcare/articles/lifestance-health-group-lfst-tops-113503644.html
LifeStance Health Group (LFST) reported strong Q3 2026 results, surpassing Zacks Consensus Estimates for both earnings and revenue. The company posted adjusted earnings of $0.06 per share, double the consensus estimate, and revenues of $455.86 million, exceeding estimates by 6.31%. LifeStance Health's stock has seen a significant 101.9% gain year-to-date, outperforming the S&P 500.

LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/lifestance-reports-strong-third-quarter-2026-financial-results-and-raises-full-year-outlook/2462699
LifeStance Health Group, Inc. announced strong financial results for the third quarter of 2026, with revenue increasing 25% to $455.9 million and Adjusted EBITDA growing 70% to $68.4 million. The company also raised its full-year 2026 outlook across all financial metrics, including revenue expectations of $1.741 billion to $1.761 billion. CEO Dave Bourdon highlighted the team's strong execution and investments in their platform, positioning LifeStance for continued long-term success.

LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

https://www.stocktitan.net/news/LFST/life-stance-reports-strong-third-quarter-2026-financial-results-and-8vsjy66zqu5r.html
LifeStance Health Group (Nasdaq: LFST) reported strong third-quarter 2026 financial results, with revenue increasing 25% year-over-year to $455.9 million and net income rising significantly to $22.4 million. The company also raised its full-year 2026 financial outlook across all key metrics, including revenue expectations to $1.741 billion to $1.761 billion and adjusted EBITDA to $242 million to $250 million. This performance was driven by higher visit volumes, clinician growth, and improved operating leverage, demonstrating continued momentum and confidence in future growth.
Advertisement

LifeStance Health Group, Inc. (LFST) Seasonal returns chart

https://uk.finance.yahoo.com/quote/LFST/seasonality/
The article provides a seasonal returns chart for LifeStance Health Group, Inc. (LFST), displaying the average monthly price return from 2021 to 2026. As of October 30, LFST's stock price was $13.40, with a slight decrease of 1.72% at market close. The page includes financial data and historical seasonality for the company.

LifeStance Health Group, Inc. (LFST) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6795_QuantitativeReport_1793145600000
LifeStance Health Group Inc. (LFST) has received a "HOLD" Investment Rating from Argus, with a target price raised to $14.00. The company's industry, management, safety, financial strength, growth, and value subratings are all set at Medium. This report was published on October 28, 2026.

In one depression-treatment analysis, near-daily suicidal thoughts fell from 13% to 2%.

https://www.stocktitan.net/news/LFST/life-stance-patients-with-treatment-resistant-depression-see-5b2hngs4ysfa.html
LifeStance Health announced that separate analyses of esketamine and transcranial magnetic stimulation (TMS) treatments for treatment-resistant depression showed significant symptom improvements. Among esketamine patients, 74% saw a clinically meaningful reduction in depression severity and nearly daily suicidal ideation decreased from 13% to 2%. TMS patients experienced similar benefits, with 61% showing improvement and suicidal ideation falling from 13% to 6%, leading LifeStance to expand access to these specialty services.

LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows

https://www.prnewswire.com/news-releases/lifestance-patients-with-treatment-resistant-depression-see-clinically-meaningful-improvement-in-symptoms-after-esketamine-or-tms-treatment-new-data-shows-302922942.html
LifeStance Health announced new data showing that patients with treatment-resistant depression experienced clinically meaningful improvements in symptoms and reductions in suicidal ideation after receiving esketamine or transcranial magnetic stimulation (TMS) treatment. The company is significantly expanding access to these specialty services across the U.S. to provide more options for patients who have not found relief from conventional treatments.

Lifestance Health stock hits 52-week high at $13.57

https://www.investing.com/news/company-news/lifestance-health-stock-hits-52week-high-at-1357-93CH-4980516
LifeStance Health Group Inc. (LFST) reached a new 52-week high of $13.57, pushing its market capitalization to $5.16 billion, reflecting a 168.07% stock price increase over the past year. This comes after the mental health provider reported strong Q2 2026 financial results, surpassing analyst expectations with significant revenue and adjusted EBITDA growth. Investment firms like KeyBanc and Canaccord have raised their price targets for LFST, citing confidence in its strategic positioning and leadership in mental health services.
Advertisement

(LFST) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/35/LFST_and_the_Role_of_Price-Sensitive_Allocations_102826013801_1793165881.html
This article provides an analysis of Lifestance Health Group Inc. (NASDAQ: LFST), highlighting strong sentiment across all time horizons supporting an overweight bias. It details an exceptional 40.0:1 risk-reward setup targeting a 13.0% gain versus a 0.3% risk. The analysis also presents three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis.

LifeStance Health Group, Inc. Estimates – NASDAQ:LFST

https://www.tradingview.com/symbols/NASDAQ-LFST/financials-estimates/
This article provides an overview of LifeStance Health Group, Inc. (NASDAQ: LFST) financials and analyst estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics, allowing comparison of actual results with average, high, and low estimates. The platform also offers tools to visualize trends over time for the income statement, balance sheet, and cash flow on both annual and quarterly bases.

A Look at LifeStance Health Group Inc (LFST) After 3.8% Gain -- GF Value $8.88 vs Price $12.22

https://www.gurufocus.com/news/9132926/a-look-at-lifestance-health-group-inc-lfst-after-38-gain-gf-value-888-vs-price-1222
LifeStance Health Group Inc (LFST) saw its shares rise by 3.8% to $12.22, yet GuruFocus estimates its intrinsic value (GF Value™) at $8.88, indicating the stock is significantly overvalued by 37.6%. Despite a strong GF Score™ of 81/100, signaling solid fundamentals and growth potential, substantial insider selling totaling $847.2M without any buying activity raises concerns about the stock's future performance and current valuation. Investors are advised to exercise caution due to the overvaluation and insider sentiment.

LifeStance Health Group Inc (LFST) Shares Fall 5.1% -- GF Value Says Still Overvalued

https://www.gurufocus.com/news/9128555/lifestance-health-group-inc-lfst-shares-fall-51-gf-value-says-still-overvalued
LifeStance Health Group Inc (LFST) shares dropped 5.1% to $11.74, trading 32.5% above its GF Value estimate of $8.86, indicating it is overvalued. Despite its P/E ratio being below its 5-year median, insider selling of $847.2 million over the past year without any buying suggests a lack of confidence from within the company. LFST holds a GF Score of 78/100, showing strengths in growth and financial strength but weaknesses in valuation, cautioning investors due to potential overvaluation risks.

LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026

https://www.manilatimes.net/2026/10/16/tmt-newswire/globenewswire/lifestance-to-host-third-quarter-2026-earnings-conference-call-on-november-5-2026/2447062/amp
LifeStance Health Group, Inc. (NASDAQ: LFST) will release its third-quarter 2026 earnings before the market opens on Thursday, November 5, 2026. The company will also host a live earnings conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. Interested parties can access the call via phone or a real-time audio webcast on the LifeStance Investor Relations website.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement